December 2024 in “Journal of Cancer Therapy and Research” Artocarpus heterophyllus seed extract may help treat prostate inflammation without side effects.
22 citations
,
September 2002 in “Der Urologe” Alpha1-blockers effectively improve urinary symptoms in BPH, with alfuzosin and tamsulosin having fewer side effects.
1 citations
,
January 2010 in “Endocrine abstracts”
14 citations
,
November 2006 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.
2 citations
,
March 2016 in “The Journal of Urology” Male infertility often lacks thorough investigation, potentially missing reversible causes.
December 2025 in “Journal of the European Academy of Dermatology and Venereology” 35 citations
,
May 2002 in “Journal of the European Academy of Dermatology and Venereology” Chronic pelvic pain in men is common, but its cause is unknown and treatments are often ineffective.
23 citations
,
June 1999 in “Clinical Therapeutics” Finasteride is a cost-effective option for treating BPH, reducing risk of urinary issues and surgery.
127 citations
,
May 2004 in “PubMed” Finasteride may help some male chronic pelvic pain patients, but more research needed.
22 citations
,
November 2020 in “Frontiers in Physics” Proton minibeam radiotherapy shows promise for sparing healthy tissue in cancer treatment but needs further research and technological development.
2 citations
,
February 2006 in “Mayo Clinic Proceedings” Finasteride is beneficial for BPH but requires careful monitoring due to cancer risks.
September 2023 in “Journal of the American Academy of Dermatology”
1 citations
,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
14 citations
,
December 2003 in “BJUI” Finasteride can treat prostatic haematuria, but its use is controversial.
March 2026 in “Journal of Multidisciplinary Applied Natural Science” Cosmos caudatus extract is as effective as finasteride for treating benign prostatic hyperplasia without its side effects.
1 citations
,
January 2002 in “European Urology Supplements” Tamsulosin works faster, but both drugs have similar effects after 6 months.
15 citations
,
March 2014 in “Molecular Medicine Reports” α-spinasterol from Melandrium firmum can help reduce prostate enlargement.
9 citations
,
October 2013 in “PLOS ONE” Dutasteride works better than finasteride for preventing and treating prostate cancer.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
5 citations
,
January 2018 in “Interdisciplinary sciences: computational life sciences” Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.
October 2020 in “Cirugía y cirujanos” Obesity is linked to more severe lower urinary tract symptoms.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
January 2021 in “Faculty of 1000 Research Ltd” Phytochemicals may offer safer alternatives to synthetic drugs for prostate cancer treatment.
7 citations
,
September 2014 in “Mass spectrometry letters” The best method to monitor dutasteride in rat plasma is liquid-liquid extraction with methyl tert-butyl ether and methylene chloride.
January 2013 in “The Journal of Sexual Medicine” The document suggests that finasteride may cause depression and suicidal thoughts, while prostate surgery does not harm sexual health.
50 citations
,
January 2008 in “International Journal of Antimicrobial Agents” Alpha-blockers are recommended first for recent CP/CPPS, while antimicrobials are not advised for long-term cases.
6 citations
,
February 2013 in “Medical Oncology” Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.
54 citations
,
November 2001 in “Urology” The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
45 citations
,
August 2010 in “Hormone Molecular Biology and Clinical Investigation” Type 3 5α-reductase is more common and finasteride and dutasteride strongly inhibit it.